These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 37891550

  • 1. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
    Chen JY, Pan HC, Shiao CC, Chuang MH, See CY, Yeh TH, Yang Y, Chu WK, Wu VC.
    Cardiovasc Diabetol; 2023 Oct 27; 22(1):290. PubMed ID: 37891550
    [Abstract] [Full Text] [Related]

  • 2. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T, Hadnorntun P, Leelahavarong P, Kongmalai P, Srinonprasert V, Chirakarnjanakorn S, Chaikledkaew U, McKay G, Attia J, Thakkinstian A.
    Front Endocrinol (Lausanne); 2023 Oct 27; 14():1216160. PubMed ID: 38179304
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY, Liu SY, Yin DG.
    Medicine (Baltimore); 2021 Jul 30; 100(30):e26431. PubMed ID: 34397684
    [Abstract] [Full Text] [Related]

  • 4. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb 30; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 5. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN, Ting AZH, Teo YH, Chong EY, Tan JTA, Syn NL, Chia AZQ, Ong HT, Cheong AJY, Li TY, Poh KK, Yeo TC, Chan MY, Wong RCC, Chai P, Sia CH.
    Am J Cardiovasc Drugs; 2022 May 30; 22(3):299-323. PubMed ID: 35316484
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials.
    Kani R, Watanabe A, Miyamoto Y, Ejiri K, Iwagami M, Takagi H, Slipczuk L, Tsugawa Y, Aikawa T, Kuno T.
    J Am Heart Assoc; 2024 Feb 06; 13(3):e031805. PubMed ID: 38293914
    [Abstract] [Full Text] [Related]

  • 7. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
    Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I.
    Cardiovasc Diabetol; 2022 May 18; 21(1):67. PubMed ID: 35585590
    [Abstract] [Full Text] [Related]

  • 8. SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Chen HB, Yang YL, Yu TH, Li YH.
    Eur J Pharmacol; 2022 Dec 05; 936():175354. PubMed ID: 36306924
    [Abstract] [Full Text] [Related]

  • 9. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
    Täger T, Frankenstein L, Atar D, Agewall S, Frey N, Grundtvig M, Clark AL, Cleland JGF, Fröhlich H.
    Clin Res Cardiol; 2022 Apr 05; 111(4):428-439. PubMed ID: 34498169
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.
    Chen HB, Yang YL, Meng RS, Liu XW.
    ESC Heart Fail; 2023 Apr 05; 10(2):1231-1241. PubMed ID: 36702979
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
    Shao SC, Chang KC, Lin SJ, Chang SH, Hung MJ, Chan YY, Lai EC.
    Cardiovasc Diabetol; 2021 Oct 23; 20(1):213. PubMed ID: 34688282
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.
    Xie Y, Wei Y, Li D, Pu J, Ding H, Zhang X.
    J Cardiovasc Pharmacol; 2023 Jan 01; 81(1):4-14. PubMed ID: 36607775
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
    Rodriguez R, Kaluzna SD.
    Am J Health Syst Pharm; 2023 Jun 22; 80(13):818-826. PubMed ID: 36971375
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials.
    Lee MC, Hua YM, Yang CT, Kuo FH, Chang WT, Tang HJ, Siong Toh H, Lin YM, Chen SY, Chang HY, Liao CT.
    Medicine (Baltimore); 2022 Dec 23; 101(51):e32489. PubMed ID: 36595871
    [Abstract] [Full Text] [Related]

  • 19. Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring.
    Ghosal S, Sinha B.
    Front Endocrinol (Lausanne); 2023 Dec 23; 14():1168755. PubMed ID: 37469980
    [Abstract] [Full Text] [Related]

  • 20. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.
    Aziri B, Begic E, Jankovic S, Mladenovic Z, Stanetic B, Kovacevic-Preradovic T, Iglica A, Mujakovic A.
    ESC Heart Fail; 2023 Jun 23; 10(3):1499-1530. PubMed ID: 36967133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.